Introduction
HER2 (also known as erbB2) and its relatives HER1 (epidermal growth factor receptor; EGFR), HER3 and HER4 belong to the HER family of receptor tyrosine kinases. Individual features of this group of receptors include the ligand-less HER2 receptor and the kinasedead HER3 receptors (Ullrich et al., 1984; Coussens et al., 1985; Kraus et al., 1989; Plowman et al., 1993) . A large family of ligands (reviewed in Yarden, 2001) induces receptor dimerization, with each ligand favoring some dimeric combinations over others in a specific hierarchical order, although a marked preference for HER2 as a dimer partner has been described Graus-Porta et al., 1997) . Several mechanisms allow HER2 heterodimers, the most prevalent dimers in several human tissues, to generate a stronger intracellular signal than that originating from other complexes (reviewed in Yarden, 2001) . In normal cells, activation of this receptor tyrosine kinase family triggers a rich network of signaling pathways that control normal cell growth, differentiation, motility, and adhesion in several cell lineages (Gassmann et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995; Threadgill et al., 1995; Sibilia et al., 1998) . The formation of heterodimers and the ensuing activation are temporary and spatially controlled in normal cells and tissue, but dysregulation of this network has been reported in cancer cells, where increased expression levels of HER2 (e.g., in breast cancer) (Pierce et al., 1991; Liu et al., 1995) or HER1 (e.g., in lung cancer) provided a growth advantage. Indeed, overexpression of HER2, which occurs in about 30% of breast and ovarian cancers (Slamon et al., 1989) , activates the PI3K/Akt 'survival' pathway, whose action favors cell proliferation apparently by inhibiting apoptosis (Di Fiore et al., 1987; Liu et al., 1995; Muthuswamy et al., 2001; Zhou and Hung, 2002) . The 'survival' signal is normally coupled to the activation of the mitogenic signal involving MAPK-pathway recruitment. Increased HER2 expression in cancer enhances and prolongs signaling from both the PI3K/Akt and MAPK pathways Waterman et al., 1999) , associating upregulation of this receptor to the malignant phenotype.
Nevertheless, HER2 signaling is carefully regulated in cells and excess signaling induces apoptosis in cells carrying a wild-type p53 gene (Peles et al., 1992; Daly et al., 1997 Daly et al., , 1999 Giani et al., 1998) . This observation implies the presence of other alterations related to the apoptotic pathway in tumor cells that allow the shift from apoptosis to proliferation and survival in the face of HER2 oversignaling (Casalini et al., 2001; Huang et al., 2002) . Recent proof that HER2 induction of proliferation in a normal mammary cellular context requires cooperation with survival-promoting factors supports the idea that the type of signal originating from overexpressed HER2 depends on additional defects in cell cycle control and suppressor gene activity (Debnath et al., 2002) .
The tumorigenic action of HER2 is not limited to a potential proliferative effect. In fact, HER2 has been shown to be a metastasis-promoting factor. Changes in HER2 levels and in its activation by different EGF-like and heregulin (HRG) ligands have been associated with increased invasiveness in vitro and a more metastatic phenotype in vivo. A key role for HER family members in enhancing metastatic potential rests in their ability to promote secretion of basement membrane degradative enzymes, such as the matrix metalloproteases (MMPs) (Tan et al., 1997; O-charoenrat et al., 1999) , which determine modifications in the tissue architecture through the breakdown of the matrix and consequent perturbations of cell-cell and cell-matrix interactions. These alterations, together with changes in integrin and cadherin function frequently observed in tumor cells with activated HER, facilitate the communication between tumor cells and their escape from control by the microenvironment. In particular, the creation of new interactions of HER family members with integrins, such as HER2 and a 6 b 4 ( Figure 1 ) and focal adhesion kinases recruits the PI3 K pathway (Campiglio et al., 1994; Tagliabue et al., 1996; Gambaletta et al., 2000) , inducing the release of second messengers (phosphoinositides and calcium). These molecules in turn recruit multiprotein complexes that play a role in reorganization of actin cytoskeleton, and thus in tumor cell migration (Dittmar et al., 2002; Feldner and Brandt, 2002) . Moreover, the high expression of HER2 in invadopodia of cancer cells suggests its involvement in cell migration (Eccles, 2000; Dittmar et al., 2002) . Although those interactions remain to be studied further, the current body of information points to a predominant role for HER2 in motogenic and mitogenic signaling, whereas HER1 signaling appears to control the proteolysis of the matrix, mainly by inducing MMPs, and invasion (Tan et al., 1997; O-charoenrat et al., 1999; Dittmar et al., 2002; Feldner and Brandt, 2002) . By upregulating specific MMPs and angiogenic factors, such as VEGF (Kerbel et al., 2000) , and by potentiating the adhesion of tumor cells to endothelial cells, activated HER members enhance angiogenesis and vascular invasion.
Notwithstanding the abundance of studies on the biology of HER2 and its receptor family, many pathways interacting with HER2 are still not fully understood or exploited for therapeutic purposes.
HER2 status assessment in tumors
The literature reveals a wide variation in HER2 levels (Me´nard et al., 2001a) within a single tumor type, most probably attributable to the lack of standardized methodologies used to assess HER2 status. The advent of standardized, FDA-approved tests for protein overexpression by immunohistochemistry (IHC) or gene amplification by FISH has led to an overall improvement in HER2 status assessment Paik et al., 2002; Rhodes et al., 2002) , as indicated by several quality-control studies performed around the world (Arch. Pathol. Lab. Med., 2002; Roche et al., 2002) . However, evaluation even with standardized IHC methodology has demonstrated wide variation in HER2 overexpression rates in different tumor types. The highest frequency of HER2 overexpression is found in inflammatory breast cancers scoring 3 þ with herceptest in more than 60% of the cases (Tagliabue et al., 1998) , followed by Wilm's tumor (50%), bladder cancer (44%), and noninflammatory breast cancer (25%). In other tumors, including pancreatic, colon, ovary, and lung tumors, the frequency of HER2 overexpression differs in different reports and is often greater than predicted by gene-amplification data (Kim et al., 2000; Geddert et al., 2002; Goebel et al., 2002; Hirsch et al., 2002; Khan et al., 2002; Latif et al., 2002; Soule et al., 2002; Yan et al., 2002; Nakamura et al., 2003) , suggesting that overexpression in these tumors is due to gene deregulation rather than gene amplification. New therapeutic tools targeting HER2 are now being investigated mainly for therapy of breast carcinomas, in which overexpression is mainly due to gene amplification. 
HER2 status in prognosis and prediction of response to therapy
Various clinical studies have evaluated the relationship between HER2 and breast cancer outcome, and most have shown that women with HER2-positive tumors have a poorer prognosis than women with HER2-negative tumors (Me´nard et al., 2000 (Me´nard et al., , 2001b Masood and Bui, 2002) . However, while the prognostic value of HER2 amplification/overexpression in node-positive patients has been widely demonstrated, there is no consensus on its value in node-negative cases (Press et al., 1997; Ross et al., 1998; Volpi et al., 2000; Cooke et al., 2001) . Although a few studies on small series have shown some prognostic impact of HER2-positivity in node-negative patients, others, including our study of a large cohort of node-negative cases, argue against a prognostic role for HER2 in this patient subset ( Figure 2 ) (Me´nard et al., 2002) . Moreover, in a recent microarray analysis to identify genes associated with poor prognosis (poor signature) and good prognosis (good signature) in node-negative patients, HER2 was not included in the 70 prognostic genes identified ( Van'T Veer et al., 2002) .
In any event, the prognostic impact of HER2 positivity is related only to the first 3-4 years after surgery, as indicated by the peak of early recurrences (Me´nard et al., 2002) . The reasons for the early recurrences in HER2-positive tumors have been suggested to rest in events occurring at the time of surgery. Indeed, growth factors released during wound healing (Murthy et al., 1989; Sieweke and Bissell, 1994) have been shown to preferentially stimulate the growth of HER2-positive tumors (Tagliabue et al., 2001) . These growth factors are more likely to have a stimulatory effect in patients with disseminated micrometastasis (node-positive patients) of an HER2-positive tumor, which might also explain the prognostic impact of HER2 according to nodal status.
There is considerable interest in biologic markers able to predict the response of cancer patients to therapy. HER2 overexpression has been implicated as a potential indicator of responsiveness to doxorubicin. Indeed, the study by the Cancer and Acute Leukemia Group B (CALGB) of node-positive patients randomly allocated to three dose levels of cyclophosphamide, doxorubicin and fluorouracil (CAF) (Thor et al., 1998) , as well as the study by Paik et al. (1998) from the National Surgical Adjuvant Breast and Bowel Project (NSABP) examining the effect of doxorubicin in node-positive patients, and others (Di , indicated that administration of doxorubicin was of significant benefit in HER2-positive tumors, but without any beneficial effect in HER2-negative tumors.
Contrary to expectations based on most previous studies, HER2-positive tumors were recently shown to benefit from cyclophosphamide, methotrexate, and fluorouracil (CMF) treatment (Miles et al., 1999; Me´nard et al., 2001c) ; however, addition of doxorubicin to the CMF regimen further improved survival only in patients with HER2-positive tumors (Table 1 ) (Moliterni et al., 2003) . HER2 positivity has been related to endocrine therapy unresponsiveness, even in hormone receptor-positive patients (Grunt et al., 1995; Elledge et al., 1998) . The recent observation that the level of expression of estrogen receptor is inversely correlated with HER2 expression (Konecny et al., 2003) , together with clinical data indicating that only high estrogen receptor-expressing tumors are sensitive to the antiestrogen reagent tamoxifen (Early Breast Cancer Trialists' Collaborative Group, 1998), likely explain the tamoxifen resistance of HER2-positive tumors.
HER2 in the molecular portrait of breast carcinomas
A new subset classification of breast carcinomas has recently been proposed based on the gene expression profile revealed by microarray analysis (Perou et al., 2000; Sorlie et al., 2001) . HER2 overexpression, which is associated with overexpression of other genes that are probably coamplified in the same amplicon, together with a series of other coexpressed genes, has been reported to identify a subset of tumors characterized by the lack of expression of genes associated with hormone receptor-signaling pathway, high-level expression of a cluster of genes associated with proliferation, and expression of keratins associated with undifferentiated stem cells (Bocker et al., 2002) . These findings suggest a pattern of gene expression peculiar to HER2-expressing tumors, and raise the possibility that all the clinical features thus far associated with HER2, for example, prognosis, prediction of response to therapy, might actually be related to the biological behaviors of the subset and not directly to the presence of the oncoprotein. For example, sensitivity to anthracyclins might be related to the growth characteristics of the HER2-expressing subset rather than to the HER2 receptor pathway itself, as also suggested by in vitro studies (Campiglio et al., 2003) .
HER2 as a target for therapy
Passive immunotherapy Differential levels of HER2 expression in normal versus HER2-overexpressing tumor cells, together with the clear involvement of HER2 in tumor progression, make HER2 an ideal target for therapeutic approaches. Monoclonal antibodies specifically directed against the extracellular domain of HER2 have been shown to selectively inhibit growth of HER2-overexpressing cancer cells. One such antibody, 4D5 (Fendly et al., 1990) recognizes an extracellular epitope in the cysteine-rich II domain, residing very close to the transmembrane region (De Santes et al., 1992) . To facilitate clinical use, 4D5 has been humanized at Genentech (South San Francisco, CA, USA) by inserting its complementary-determining regions (CDR) into the human immunoglobulin G1 framework (Carter et al., 1992) . The therapeutic activity of the humanized antibody, known as trastuzumab, has been evaluated as a single agent given before (Vogel et al., 2002) or after (Cobleigh et al., 1999) traditional chemotherapy, and in combination with a variety of chemotherapy agents (Slamon et al., 2001) , in women with HER2-overexpressing metastatic breast cancer. The results indicated a therapeutic benefit of addition of trastuzumab to the therapeutic protocol. A recent study has also shown that preoperative trastuzumab in combination with other chemotherapeutic agents was active against HER2-overexpressing early-stage breast cancer (Burstein et al., 2003) . Thus, trastuzumab has become a standard of care for women with HER2-overexpressing metastatic breast cancer and its clinical efficacy seems to be clear. However, the in vivo mechanism(s) of action of this reagent is not completely understood, and analyses of trastuzumab activity in experimental models have evidenced at least three different possible mechanisms: HER2 downregulation, antibody-dependent cell cytotoxicity (ADCC), and alteration of vessel development. In vitro treatment of HER2-overexpressing breast carcinoma cell lines with trastuzumab resulted in downmodulation of the receptor and inhibition of tumor growth (Hudziak et al., 1989; Hieken et al., 1996) . Indeed, trastuzumab induces obligate formation of HER2 homodimers, leading to an increase of ligand-mediated endocytosis of the receptor and, consequently, to significant removal of HER2 from the plasma membrane and decreased receptor-initiated constitutive signaling (Hudziak et al., 1989; Sarup et al., 1991; De Santes et al., 1992) . Several other phenotypic changes accompany trastuzumab binding to HER2-overexpressing cells in vitro, including induction of p27 KIP1 and of the Rb-related protein, Rb2/p130, with consequent reduction of the number of cells in S phase (Sliwkowski et al., 1999) . To date, experiments evidencing a trastuzumab dose-dependent antitumor effect on human tumor cell lines xenografted in athymic mice have not included analysis of disappearance of the receptor . In contrast, the activity of trastuzumab examined in animal models was found to depend on the engagement of Fc-receptor expressing lymphocytes (Clynes et al., 2000) , indicating ADCC as the major mechanism of antibody action. In FcRg þ / þ nude mice injected subcutaneously with HER2-overexpressing human breast carcinoma cells, trastuzumab treatment resulted in near-complete (96%) inhibition of tumor growth. This protective effect was reduced more than 50% after disrupting the antibody's ability to engage cellular Fcg receptor or in antibody-treated FcRg À/À mice. Clearly, the precise delineation of trastuzumab mechanism of action in patients is essential for the design of more successful antibody treatment protocols in breast carcinoma patients. If, in fact, the major mechanism is ADCC, the combination of trastuzumab with immunosuppressive chemotherapeutic drugs requires optimal timing of trastuzumab delivery to enable rescue of ADCC effectors such as NK cells after chemotherapy. In that context, clinical studies have demonstrated a synergistic action between trastuzumab and the drug taxane (Slamon et al., 2001) , which induces suppression of adaptive immunity, but selectively increases NK activity (Tsavaris et al., 2002) . To improve therapeutic activity, stimulation of NK activity might also be considered, utilizing cytokines or 'danger signals' such as unmethylated CpG-oligodeoxynucleotides that enhance innate immunity (Sfondrini et al., 2002) . A recent study in a preclinical model consisting of immunodeficient SCID mice transplanted with human breast carcinoma cells overexpressing HER2 showed that trastuzumab treatment induced a 30% reduction of tumor volume as well as a reduction in vessel volume, introducing a new mechanism of action for this antibody (Izumi et al., 2002) . However, this finding does not necessarily exclude ADCC since in a model such as the SCID mouse, which is profoundly deficient in T and NK cells, inhibition of HER2-driven pathways by the anti-HER2 antibody may contribute significantly to antitumor efficacy. Indeed, HER2 signaling is known to control the expression of pro-and antiangiogenic factors, including VEGF (Kerbel et al., 2000) , PAI-1 (Allgayer et al., 2000) , TGFa (Nicolini et al., 1996) , and TSP-1 (Izumi et al., 2002) . The antitumor activity through vessel regression, together with the low protection exerted by trastuzumab found in mice knocked out for the Fc receptor, suggest that trastuzumab can utilize different mechanisms in vivo, but that ADCC remains the most potent in tumor inhibition.
Active immunotherapy Cancer vaccination is based on the induction of a long-lasting immunologic memory provided by expanded populations of T-and Blymphocytes with cytotoxic potential and tumor antigen specificity.
Although HER2 is generally indicative of a poor prognosis, its overexpression is associated with a better outcome when inflammatory infiltrates are present in the tumor, suggesting a role for HER2 in tumor immunosurveillance (Rilke et al., 1991; Me´nard et al., 1996; Pupa et al., 1996) . In keeping, development of HER2-specific antibodies has been documented in patients with primary HER2-positive tumors (Pupa et al., 1993; Disis et al., 1994 Disis et al., , 1997b , and T cells reactive to HER2 were found to occur in patients with HER2-positive tumors (Disis and Cheever, 1997a) , confirming the immunogenicity of the molecule.
HER2-derived vaccines have been used in efforts to redirect immunity to induce rejection of HER2-positive tumors (Foy et al., 2002; Kiessling et al., 2002) . Immunization regimens of active immunotherapy have been devised that generate specific T-cell responses with or without accompanying antibody responses and are currently being tested in animal models or in clinical trials (Rovero et al., 2000; Di Carlo et al., 2001; Nanni et al., 2001; Foy et al., 2002; Kiessling et al., 2002) .
In oncology, the notion of vaccination has shifted from preventive to therapeutic (Colombo and Forni, 1996) , since cancer patients are immunized after a tumor is detected, in contrast to traditional immunization with microbial vaccines administered prior to encounter with the pathogen. Animal studies have shown that cancer vaccines generally display only limited or no efficacy in curing established tumors in syngeneic models (Lollini and Forni, 2002) with some exceptions (Mayordomo et al., 1995; Zitvogel et al., 1996; Nagata et al., 1997; Haynes et al., 2002) . Furthermore, the limited therapeutic efficacy of vaccines was lost when they were not given in the first few days after tumor cell implantation when tumor burden is still very small (Cavallo et al., 1997 (Cavallo et al., , 1999 Nanni et al., 1999) . These experimental findings point to the need for better selection of patients for enrollment in immunotherapy trials, such as patients with a minimal residual disease after conventional treatments or patients bearing tumors at an early stage of disease, to allow more reliable and objective clinical results (Bocchia et al., 2000; Forni et al., 2000; Finn and Forni, 2002; Jager et al., 2002) .
Immunotherapeutic strategies such as immunization with MHC class I-and class II-restricted HER2-specific peptides with or without adjuvants, HER2 DNA, HER2 recombinant protein, and dendritic cells loaded with HER2 peptides are now being tested in animal models and phase I clinical trials (Knutson et al., 2001; Disis et al., 2002; Foy et al., 2002; Kiessling et al., 2002) . The vaccine preparation consisted of HER2 peptides containing putative T-helper epitopes and HLA-A2-binding Role of HER2 in cancer S Menard et al motifs, with recombinant human GM-CSF administered as adjuvant. In the majority of immunized patients, long-lasting T-cell-mediated immunity was revealed by in vitro and in vivo monitoring and, most importantly, immunity to the HER2 protein was significantly associated with epitope 'spreading,' reflecting the initiation of an endogenous immune response (Disis et al., 2002) . Most cancer vaccines have been found to induce both T-and B-cell responses, even when no therapeutic benefits on experimental implanted tumors are observed. It remains unclear why anti-HER2 antibodies induced by active immunization are not therapeutically active on implanted autologous growing tumors, whereas monoclonal antibodies such as trastuzumab are. Quantity as well as quality of the induced antibodies might be involved; indeed, monoclonal antibodies for use in passive immunotherapy are strongly selected and used at optimized concentrations, which is not the case for antibodies induced by active immunization.
While poorly active in inducing an antitumor therapeutic response, most of the vaccines are effective in preventing spontaneous tumor occurrence (Figure 3 ) (Finn and Forni, 2002) . Most data on the preventive potential of HER2 vaccines have come from studies in genetically predisposed animals transgenically expressing the rat HER2/neu proto-oncogene or its mutated activating form, and which are tolerant to self neu (De Vecchi et al., 1999) . Different vaccination strategies include: rat HER-2/neu-positive allogeneic cells alone (Cefai et al., 1999) or in combination with interleukin-12 ; the extracellular domain of the rat oncoprotein (Esserman et al., 1999) or peptides derived from it (Dakappagari et al., 2000) ; and DNA plasmids encoding different fragments of activated rat neu gene or the HER2 full-length gene (Amici et al., 2000; Rovero et al., 2000; Pupa et al., 2001) .
Immunological interventions targeting the HER2 protein, which is expressed at basal levels on adult normal tissues (Press et al., 1990) , have raised safety concerns with respect to the potential induction of autoimmune toxicity; however, at present, no pertinent data in tumor-bearing hosts have been obtained (Ludewig et al., 2000; Kiessling et al., 2002; Ohashi and DeFranco, 2002) .
The overall mechanism by which anti-HER2 vaccination exerts a preventive effect appears to involve a reduction in the number of normal epithelial mammary cells, although a contribution of a therapeutic effect on occult tumors cannot be excluded. Therapeutic and prophylactic cancer vaccines offer the advantage of inducing the development of both T-and B-cell-mediated long-term immunity, but an optimal vaccine formulation with objective therapeutic benefits remains to be defined. This goal awaits an improved understanding of the molecular mechanisms underlying the immunological escape of HER2-positive tumors.
Antityrosine kinase receptors therapy Signals induced by HER2-containing heterodimers have the strongest biological activity, and high expression of HER2 leads to amplification of the signaling cascade induced by ligands of the HER family (Harari and Yarden, 2000; Prenzel et al., 2001) . HER2 is also the preferred partner of HER1 for heterodimer formation. Thus, inhibition of HER1 activity has been proposed as an avenue to blocking HER2 activity. The recent availability of tyrosine kinase inhibitors (TKI) that specifically block the phosphorylation and function of HER1 has provided a powerful new tool for therapy of tumors whose proliferation depends on HER1 or HER2. One such inhibitor is ZD1839 ('Iressa'), an orally active, selective HER1 TKI that induces a reversible inhibition or a delay in the growth of cancer cell lines and human tumor xenografts expressing high levels of HER1 (Sirotnak et al., 2000) . Tumors expressing only low levels of HER1, but overexpressing HER2, are also sensitive to this TKI. However, the precise mechanism through which Iressa exerts its antitumor effect remains unclear. Indeed, Iressa inhibits the growth of some breast carcinoma cell lines, but induces apoptosis in other lines. In addition, Iressa treatment of breast carcinoma cell lines expressing both HER2 and hormone receptors was found to restore the inhibitory activity of tamoxifen (Witters et al., 2002) , suggesting the usefulness of TKI-mediated disruption of HER2 signaling in abrogating the antiestrogen resistance observed in HER2-positive breast tumors.
Concluding remarks
The importance of the HER2 molecule for breast carcinoma pathology is clear, whereas for other tumors, its altered expression and role in progression require much additional study. However, even in HER2-positive breast carcinomas, some clinical behaviors of the tumors remain unexplained, despite numerous in vitro experimental studies that have elucidated the HER2-signaling pathway and its involvement in proliferation, survival, and metastasis induction. The possibility that HER2 overexpression is peculiar to a particular breast carcinoma subset which is also characterized by expression of other genes that affect patient outcome, cannot yet be excluded.
Nevertheless, the proven survival benefit of trastuzumab-driven therapy demonstrated in clinical trials suggests that HER2 is, to date, one of the most promising molecules for targeted therapy. Future efforts should fully address the mechanism(s) mediating trastuzumab activity, in order to optimize the use of this humanized antibody for all patients with HER2-overexpressing tumors. Also, the possibility to combine different immunological regimens in patients with HER2-positive tumors is under active investigation.
